Scientific Sessions 2024  /  Obesity and HFpEF: From Mechanisms to Management  /  Multisystem pathology of HFpEF in obesity
Logo

American Heart Association

  2
  0

Final ID:

Multisystem pathology of HFpEF in obesity

  • Shah, Sanjiv  ( NORTHWESTERN UNIVERSITY , Chicago , Illinois , United States )
  • Lewis, Gregory  ( MGH , Boston , Massachusetts , United States )
  • Sauer, Andrew  ( Saint Lukes Mid America Heart Inst , Kansas City , Missouri , United States )
    • Author Disclosures:
    Sanjiv Shah: DO have relevant financial relationships ; Consultant:Bayer:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Axon Therapies:Active (exists now) ; Consultant:Corvia :Active (exists now) ; Consultant:Boehringer-Ingelheim:Active (exists now) ; Consultant:Bristol-Myers Squibb:Active (exists now) ; Consultant:Ionis:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Tenax:Active (exists now) ; Consultant:Intellia:Active (exists now) ; Consultant:Rivus:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Pfizer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) | Gregory Lewis: DO have relevant financial relationships ; Research Funding (PI or named investigator):National Institutes of Health (R01-HL 151841, R01-HL131029, and R01-HL159514); Amgen; Cytokinetics; Applied Therapeutics; AstraZeneca; Imbria; Rivus; SoniVie; Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Rivus:Active (exists now) ; Research Funding (PI or named investigator):Astra Zeneca:Past (completed) ; Advisor:Ask Bio:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Applied Therapeutics:Past (completed) ; Consultant:Edwards:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):Cytokinetics:Active (exists now) ; Research Funding (PI or named investigator):Americal Heart Associiation:Active (exists now) | Andrew Sauer: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Researcher:35 Pharma:Active (exists now) ; Researcher:RIVUS:Active (exists now) ; Researcher:Astra Zeneca:Active (exists now) ; Researcher:CSL Vifor:Active (exists now) ; Researcher:Bayer:Active (exists now) ; Individual Stocks/Stock Options:ISHI:Active (exists now) ; Consultant:Story Health:Active (exists now) ; Consultant:General Prognostics:Active (exists now) ; Consultant:Acorai:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:Impulse Dynamics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Obesity and HFpEF: From Mechanisms to Management

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
The Intertwined Epidemics of Obesity and HFpEF: Implications for the Future of HF

Pandey Ambarish, Tsao Connie

Exercise training for HFpEF in obesity: approach and clinical impact

Levine Benjamin, Kitzman Dalane, Laddu Deepika

More abstracts from these authors:
Orthostatic Pulse Pressure, A Novel Indicator of Preload Insufficiency, May Predict Clinical Response to SGLT2 Inhibition in HFpEF: Findings from the PRESERVED-HF Trial

Yaku Hidenori, Kosiborod Mikhail, Shah Sanjiv, Sauer Andrew, Patel Shachi, Keefe Evan, Borlaug Barry, Kitzman Dalane, Windsor Sheryl, Khumri Taiyeb, Umpierrez Guillermo


Revolutionizing the Electronic Medical Record to Optimize GDMT

Sauer Andrew, Morris Alanna

You have to be authorized to contact abstract author. Please, Login
Not Available